35 citations
,
October 2021 in “Journal of the European Academy of Dermatology and Venereology” This report describes two cases where a viral vector COVID-19 vaccine was associated with the recurrence of cutaneous lymphoma conditions that had been in remission.
119 citations
,
December 2008 in “The journal of investigative dermatology/Journal of investigative dermatology” In this study, transcutaneously applied nanoparticles and viral vectors were shown to penetrate murine hair follicles, internalize in antigen-presenting cells, and induce immune responses, suggesting a promising approach for vaccine delivery.
1 citations
,
October 1996 in “Journal of Cutaneous Medicine and Surgery” This review discusses the advancements needed for gene therapy to become commonly used in dermatology and reports no new clinical results.
7 citations
,
March 2019 in “Frontiers in Cellular and Infection Microbiology” Understanding how our bodies interact with mosquito-borne viruses is crucial because there are few treatments and vaccines.
23 citations
,
January 2022 in “Biomaterials Science” Non-viral vectors show promise for safe and effective CRISPR/Cas9 gene editing in treating diseases.
October 2022 in “International Research Journal of Modernization in Engineering Technology and Science” This review discusses the development and rapid approval of COVID-19 vaccines and notes the observation of autoimmune disorders, such as alopecia areata, following vaccination; it provides no new clinical results.
2 citations
,
October 2015 in “Human Gene Therapy” The congress highlighted new gene therapy techniques and cell transplantation methods for treating diseases.
1 citations
,
October 2022 in “Current Dermatology Reports” This review discusses various skin reactions after SARS-CoV-2 infection and COVID-19 vaccination, noting a higher incidence with mRNA vaccines than adenovirus vector vaccines, and reports no new clinical results.
April 2026 in “Portuguese Journal of Dermatology and Venereology” This review summarizes the various skin manifestations linked to COVID-19 infection, vaccination, and personal protective equipment, highlighting their clinical importance and discussing psychological stress and social isolation as additional dermatologic factors.
2 citations
,
November 2015 in “Journal of Investigative Dermatology” This study found that RANKL signaling enhances CD8+ T cell-mediated anti-viral immunity during herpes simplex virus infection by preventing apoptosis of Langerhans cells, suggesting potential therapeutic applications.
September 2025 in “Advanced Pharmaceutical Bulletin” This review highlights the promise of non-viral gene delivery systems, particularly genosomes, over traditional viral vectors due to enhanced safety and efficiency in therapeutic nucleic acid delivery for genetic diseases like cystic fibrosis and malignancies.
16 citations
,
December 2021 in “Frontiers in Endocrinology” This review discusses the role of sex hormones in COVID-19 severity and reports no new clinical results; the authors suggest further research for gender-based personalized treatment options.
3 citations
,
March 2024 in “Viruses” This study found that γδ T cells in the skin contribute to wound healing after vaccinia virus infection by promoting cytokine and growth factor induction, without affecting virus replication control.
52 citations
,
January 2021 in “Journal of Thoracic Oncology” Effective vaccines and treatments are crucial for long-term COVID-19 control.
4 citations
,
January 2021 in “Genetics and Molecular Biology” This review discusses various strategies proposed to control COVID-19 and highlights challenges related to human and viral genetic variability but reports no new findings.
185 citations
,
August 2020 in “Mayo Clinic Proceedings” This review discusses biological sex differences in COVID-19 outcomes and reports no new clinical results; it identifies a need for studies to clarify how sex influences disease progression.
52 citations
,
September 2022 in “Viruses” This review discusses the functions of SARS-CoV-2 non-structural proteins in facilitating immune evasion and highlights possible therapeutic strategies, reporting no new clinical results.
December 2023 in “Curēus” This study in a California safety net hospital found no apparent increase in alopecia areata incidence among individuals who received COVID-19 vaccination compared to those unvaccinated, with odds ratios indicating a lower risk in the vaccinated group.
17 citations
,
May 2021 in “Journal of Assisted Reproduction and Genetics” This study reviews the mechanisms by which SARS-CoV-2 may impact male fertility, noting potential disruptions in spermatogenesis and hormone secretion, and underscores the need for follow-up in recovered men.
260 citations
,
January 2019 in “Pharmaceutics” This study highlights that niosomes, or non-ionic surfactant based vesicles, offer an advantageous drug delivery system due to their stability, cost-effectiveness, and ability to enhance drug bioavailability and targeting efficiency for various therapeutic agents.
5 citations
,
September 2012 in “Springer eBooks” Nanoparticles can be used to deliver drugs to hair follicles, potentially improving treatments for conditions like acne and alopecia, and could also be used for vaccine delivery and gene therapy.
December 2024 in “Archives of Dermatological Research” The authors concluded that there is no increased association between COVID-19 vaccination and alopecia areata, and the overall incidence of the condition in vaccinated individuals matches historical controls.
3 citations
,
January 2023 in “Indian Dermatology Online Journal” This study reported a series of mild to moderate cutaneous adverse drug reactions following COVID-19 vaccination, predominantly after Covishield, with only one requiring hospitalization.
10 citations
,
January 2023 in “SAGE Open Medical Case Reports” This case report describes two acute hair-related manifestations, alopecia areata and Marie Antoinette syndrome, observed in the same patient following COVID-19 infection.
2 citations
,
February 2023 in “Vaccines” This study reported cases of post-vaccine telogen effluvium and alopecia among five individuals in Ecuador following a mixed COVID-19 vaccination regimen, typically appearing within 3 to 17 days after inoculation.
In this study, nearly two-thirds of Saudi adults reported experiencing hair loss following COVID-19 infection or vaccination, with female sex and nutritional deficiencies identified as significant correlates for this condition.
September 2022 in “Frontiers in Immunology” This study reports that comorbidities and anti-androgen therapy were associated with lower SARS-CoV-2 vaccination rates among patients with androgenetic alopecia, emphasizing the need to promote vaccination within this group.
33 citations
,
June 2021 in “Dermatologic Therapy” This study reports that a patient with subacute cutaneous lupus erythematosus experienced disease exacerbation after the first dose of the BNT162b2 mRNA COVID-19 vaccine, but tolerated the second dose without adverse reactions.
8 citations
,
July 2024 in “European journal of medical research” This study reported that alopecia areata following COVID-19 vaccination is rare, occurring mostly after the first dose and associated with several vaccine types, particularly Pfizer.
January 2025 in “Consultant” In this case report, a 56-year-old Black man experienced patchy scalp hair loss which began four months after his second COVID-19 vaccination, also considering his medical history of hypertension and type 2 diabetes.